女性腹主动脉瘤筛查成本效果的系统评价
该系统评价纳入9项研究(1项前瞻性队列和8项模拟经济模型),评估女性腹主动脉瘤筛查的成本效果。女性AAA患病率从0.004%到1.15%不等,QALY增益微小(0.00075-0.02),全女性筛查的增量成本效果比超过支付阈值;靶向筛查女性吸烟者或高风险亚组可能更具经济性。
要点
- 全女性人群AAA筛查不具成本效果。
- 靶向筛查女性吸烟者或高风险亚组可能经济可行。
- 证据确定性低至中等,需更多高质量研究。
核心结论
- 常规全女性人群AAA筛查不太可能具有成本效果,靶向高风险亚组(如女性吸烟者或高多基因风险评分者)可能更经济可行。
研究设计与样本
- 系统评价纳入9项研究:1项前瞻性队列研究和8项模拟经济模型,数据主要来自欧洲或北美人群。
主要发现
- 女性AAA患病率从0.004%(加拿大)到1.15%(英国75岁女性)不等。
- QALY增益微小,范围为0.00075到0.02。
- 除一项研究外,全女性筛查的增量成本效果比均超过典型支付阈值。
关键数值与推荐
- 全女性筛查的增量成本效果比超过典型支付阈值(除一项研究外)。
- ROBINS-I评估:6项研究为中等偏倚风险,3项为严重偏倚风险。
- GRADE评估:总体证据确定性低至中等,中等确定性支持高风险亚组靶向筛查。
临床怎么用
- 不支持对全部女性进行常规AAA筛查。
- 可考虑对高风险亚组(如女性吸烟者或高多基因风险评分者)进行靶向筛查。
局限性
- 纳入研究主要为模拟经济模型,仅1项前瞻性队列研究。
- 6项研究存在中等偏倚风险,3项存在严重偏倚风险,主要来自混杂和缺失数据。
- 总体证据确定性低至中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current abdominal aortic aneurysm (AAA) screening programmes primarily target men aged ≥ 65 years. Despite a lower prevalence, women experience higher aneurysm rupture rates, suggesting potential benefit from targeted screening. This systematic review evaluated the cost effectiveness of AAA screening in all women or high risk subgroups. DATA SOURCES: MEDLINE and Embase were searched for studies from 2000 to 2025 reporting on the cost effectiveness of AAA screening in women. REVIEW METHODS: Studies needed to include sex disaggregated outcomes, number needed to treat, costs, or health economic analyses. Data extraction followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with risk of bias assessed using the ROBINS-I V2 tool. Study PROSPERO ID: CRD420250614983). RESULTS: The initial search identified 181 records, of which nine studies were included: one prospective cohort study and eight simulation based economic models, with data primarily from European or North American populations. AAA prevalence in women varied from 0.004% (Canada) to 1.15% (UK women aged 75 years). Quality adjusted life year gains were modest from 0.00075 to 0.02. Incremental cost effectiveness ratios for screening all women exceeded typical willingness to pay thresholds in all but one study. Two studies suggested increased cost effectiveness from screening women smokers for AAA: one finding that screening women smokers yielded the most favourable incremental cost effectiveness ratio ($24 000 per quality adjusted life year) and another showing that combining polygenic risk scoring with smoking status further improved the cost effectiveness of targeted screening in women aged 65 - 70 years. ROBINS-I assessment indicated six studies at moderate and three at serious risk of bias, mainly from confounding and missing data. GRADE evaluation indicated low to moderate certainty of evidence overall, with moderate certainty supporting targeted screening in high risk subgroups. CONCLUSION: Routine population based AAA screening for all women is unlikely to be cost effective. Targeted screening of high risk subgroups, such as women smokers or those with high polygenic risk scoring, may be a more economically viable approach.
引用
- De Louche CD, Pouncey AL, Van Herzeele I, et al. Editor's Choice - Systematic Review on the Cost Effectiveness of Abdominal Aortic Aneurysm Screening in Women. Eur J Vasc Endovasc Surg. 2026. PMID: 41692118. doi:10.1016/j.ejvs.2026.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。